These platforms are highly engineered medical devices studied under controlled conditions, often in early-stage clinical trials
Activity-balanced GLP-1/GDF15 dual agonist reduces body weight and metabolic disorder in mice and non-human primates
All Simple Peptide products are labeled Research Use Only (RUO) and are intended strictly for laboratory, investigational, and scientific research purposes
The most frequently reported adverse effects of GLP-1 receptor agonists are gastrointestinal in nature, including nausea, vomiting, diarrhea, constipation, and abdominal discomfort
Goldman Sachs Research estimates that GLP-1 obesity drug prescriptions could reach 30 million Americans by 2028 if coverage barriers are resolved, representing USD 150+ billion in additional annual market potential beyond current diabetes-only prescribing